303147
Florida HIV Incidence Estimate, 2007-2010
![142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual](images/banner.jpg)
Methods: The Stratified Extrapolation Approach, developed by the CDC, determines the probability that an individual would have an HIV test during his/her period of recent infection and assigns a weight to each case deemed recent (<5 months) or long-standing. Incidence is the sum of the weighted number of infections deemed recent. The incidence estimate for each demographic category was used to calculate incidence rates for 2007-2010.
Results: Comparing 2007 to 2010, there was a 29.5% decrease in incidence numbers; however, Florida still surpassed national rates in most demographic categories with few exceptions (blacks, Hispanics and persons aged 55 and over). Incidence numbers for men who have sex with men (MSM) were higher than other transmission categories. Rates among blacks remained higher than that of other ethnic groups.
Conclusions: From 2007-2010, Florida’s incidence rate remained higher than the national rate, but has decreased significantly while the national rate remained stable. Prevention efforts should be focused on black/African Americans, MSM and persons aged 13 to 34 years as their numbers remain unacceptably high.
Learning Areas:
Conduct evaluation related to programs, research, and other areas of practiceEpidemiology
Public health or related education
Learning Objectives:
Describe 4-year HIV incidence trends in Florida
Compare Florida’s HIV incidence rates to national rates
Keyword(s): HIV/AIDS, Surveillance
Qualified on the content I am responsible for because: I have served as the Incidence Coordinator for over a year and have worked closely with CDC staff to improve and implement Incidence and Molecular HIV surveillance activities in Florida. I am the primary analyst of the annual Incidence estimate.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.